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Abstract: Novel representatives of the important group of biologically active 
dibenzosuberone derivatives were prepared: 3,7-dibromo-5-(dimethylaminoethyl-
oxyimino)-10,11-dihydro-5H-dibenzo[a,d]cyclohepta-1,4-diene (1), 3,7-dibromo-5-(3-
dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene (2) and 1,7-
dibromo-5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo-[a,d]-cycloheptene 
(3). These compounds are potential tricyclic antidepressants (TCAs), which are still the 
most frequently prescribed antidepressants in many countries. 
 
Keywords: Dibenzosuberone, tricyclic antidepressants, bromination, amitriptiline, 
noxiptiline. 
 
 
Introduction 
 
A wide range of compounds that contain in their structure the dibenzosuberone unit formed by two 
aromatic rings fused with a seven-atom cycle have been proven effective for the treatment of 
depressive disorders, nowadays a highly prevalent illness, as well as for a variety of painful conditions: 
migraine headache, noncardiac chest pain, functional dyspepsia and irritable bowel syndrome (IBS) [1-
5]. Tricyclic antidepressants (TCAs) containing dibenzosuberone moieties mostly affect the autonomic 
and central nervous systems, and traditional cyclic antidepressants, like amitriptyline (4) [6-8], 
imipramine (5) [9] and noxiptiline (6) [10,11] continue to be used as first-line agents in treating 
Molecules 2005, 10 
 
 
1430
depressive disorders and an expanding list of additional conditions [12-15], with amitriptyline being 
the most commonly prescribed TCA. 
 
CH2CH2N(CH3)2
N
CH2CH2CH2N(CH3)2 N
O CH2CH2N(CH3)24 65  
 
Although TCAs have been in use for decades they are still considered safer and more effective than 
the newer class of antidepressants, the selective serotonin reuptake inhibitors (SSRIs). The latter have 
been found to have numerous side effects that are still not well understood. No better antidepressants 
have been released heretofore and new results on available antidepressants regarding their lack of 
efficacy, unwanted secondary effects, toxicity and possible association with suicides are being 
continuously documented and evaluated [12-17]. 
In light of the obvious need to produce agents representing an improvement on both the TCA and 
the SSRI classes, we decided to revisit the tricyclic antidepressant class and to prepare new 
dibenzosuberone derivatives [18]. The preparation involved the regioselective bromination of 
dibenzosuberone and subsequent use of the isomers obtained for the synthesis of new TCAs. 
Amitriptyline and noxiptiline served as a guide in the design due to their wide efficacy spectrum, 
success in treating severe psychiatric disorders and their lower costs. The halogen group in the 
structure of some known antidepressants showed positive effect in treatment of depressive disorders 
[19-21]. 
  
Results and Discussion 
 
The starting materials, 3,7- and 1,7-dibromodibenzosuberone 7 and 8 were prepared by the method 
previously developed in our laboratory, via regioselective bromination of commercially available 
dibenzosuberone [22]. As the regiochemistry of the substitution process in the dibenzosuberone ring 
generally results in ortho and para substituted isomers with respect to an alkyl group, our method 
yields para, para as well as ortho, para substituted isomers. In this manner the 3,7- and 1,7-
dibromoderivatives have been prepared as the main products and then used for the preparation of their 
respective N,N-dialkylaminopropyl and O-alkyloxime derivatives. 
Among the other possible synthetic paths to the 3,7-dibromo derivative of noxiptiline (1), first we 
applied an indirect one to avoid the direct alkylation of the oxime 9 and possible formation of an 
N-alkyl oxime instead of expected O-alkyl one. Unfortunately this method, based on the O-alkyl 
hydroxylamine prepared by O-alkylation of hydroxylamine protected with a phtalimide group, failed at 
the N-hydroxyphtalimide alkylation stage. Abandoning the indirect approach we then used the 
selective O-alkylation of the oxime 9 under mild conditions (solvent, basic salt with an appropriate 
cation), as shown in Scheme 1. The oxime of 3,7-dibromodibenzosuberone (9) was thus prepared in 
five days by a method reported for hindered ketones [23], using two portions of four equivalents of 
hydroxylamine hydrochloride and pyridine. The next step, regioselective O-alkylation of oxime 9 [24-
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26], was performed in acetone with dimethylaminoethylchloride hydrochloride and potassium 
carbonate as the base. By this procedure O-alkylated compound 1 was obtained exclusively, with an 
overall yield of 87%. Since the alkylation of oximes as bidentate nucleophiles depends on the 
structural characteristics of the substrate, in the case of compound 9 alkylation at the less hindered 
oxygen atom was favored.  
 
Scheme 1 
 
Br BrO
NH2OHxHCl, Py, EtOH
Br Br
N
OH7 9  
 
K2CO3, acetone
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N
CH3
CH3HCl Br Br
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O CH2CH2N(CH3)21
9 +
 
 
3,7- (2) and 1,7-dibromo derivatives, 3, of amitriptyline were prepared by a two-step synthesis 
according to Scheme 2.  
Scheme 2 
O
Br R2
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Attachment of a dimethylaminopropylic functionality to the skeleton of brominated dibenzo-
suberone was achieved by a Grignard reaction [27-30]. Since the required Grignard reagent 
3-dimethylamino-1-propylmagnesium chloride is not easy to obtain, very strictly controlled reaction 
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conditions have to be employed. The free base is freshly prepared separately and the reaction is 
initiated with a more reactive alkyl halogenide and iodine. The reaction was carried out for 26 hours at 
room temperature and isolated compounds 10 and 11 were purified by chromatography on SiO2. After 
chromatographic separation 65% of the 3,7- and 32% of 1,7-dibromo derivatives 10 and 11 were 
isolated, respectively. 
Dehydration of compounds 10 and 11, obtained by the previous Grignard reaction, was carried out 
by stirring for a few hours at 4 ºC with 85% sulfuric acid. Starting with compound 10, 3,7-
dibromoamitriptyline (2) was obtained in 94% yield, but with the 1,7-dibromodibenzosuberone 11 a 
mixture of syn (Z) and anti (E) isomers with respect to the 1-Br atom, was obtained. We tried to 
separate the isomers by chromatography using various mixtures of solvents, but unfortunately without 
success. Although rotation around the double bond is impossible, the dimethylaminopropyl chain 
connected to the tricyclic ring in the carbocation 12 rotates freely (Scheme 3). Therefore, we tried to 
convert compound 3 to the thermodynamically more stable isomer by prolonged stirring in sulfuric 
acid. We anticipated that implied conclusion that in the thermodynamically controlled reaction the less 
sterically hindered anti-isomer 3E would be obtained. Indeed, under these conditions the pure E 
isomer 3E is formed in good yield. 
 
Scheme 3 
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Conclusions 
 
We have prepared 3,7-dibromo-5-(dimethylaminoethyl-oxyimino)-10,11-dihydro-5H-dibenzo- 
[a,d]cyclohepta-1,4-diene (1), 3,7-dibromo-5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-
dibenzo[a,d]cycloheptene (2) and 1,7-dibromo-5-(3-dimethylaminopropylidene)-10,11-dihydro-5H-
dibenzo[a,d]cycloheptene (3), all potential drug molecules of the tricyclic antidepressant (TCA) type. 
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Experimental 
 
General 
 
IR spectra were recorded on a Perkin-Elmer Spectrum One spectrophotometer, 1H-NMR and 13C-
NMR spectra were recorded on a Bruker 600 instrument. Shifts are given in ppm downfield from TMS 
used as an internal standard. All the mass spectra were obtained on a FTMS Finnigan 2001 DD 
spectrometer. TLC analyses were performed on Merck (Darmstadt, Germany) DC-Alufolien with 
Kieselgel 60254. Elemental analyses were done at the Central Analytical Service (CAS) of the Ruđer 
Bošković Institute. 
 
3,7-Dibromo-5-hydroxyimino-10,11-dihydro-5H-dibenzo[a,d]cyclohepta-1,4-diene (9). 
 
To a solution of compound 7 (10.98 g, 30 mmol) in abs. ethanol (100 mL) hydroxylamine 
hydrochloride (8.33 g, 120 mmol) and pyridine (9.67 g, 120 mmol) were added. The reaction mixture 
was stirred under reflux for 24 hours, then an additional four equivalents of hydroxylamine 
hydrochloride (8.33 g, 120 mmol) and pyridine (9.67 g, 120 mmol) were added. After stirring under 
reflux for 100 hours the reaction mixture was cooled, poured into water (300 mL), acidified with conc. 
hydrochloric acid and extracted with ethyl acetate (3x100 mL). The extracts were dried over anhydrous 
sodium sulfate and the solvent was evaporated. Hot n-hexane (100 mL) was added to the residue and 
the precipitated colorless crystals (10.18 g, 89%) were filtered off; mp 228-230 ºC; Rf=0.50 
(dichloromethane as eluent); IR (KBr) ν 3240, 2930, 1760, 1590 (C=N), 1565, 1475, 1420, 1405, 
1385, 1355, 1320, 1290, 1260, 1175, 1160, 1100, 1075, 1010, 965, 940, 910, 890, 830, 815, 780, 775, 
755, 715, 690, 660, 630 cm-1; 1H-NMR (DMSO-d6), δ: 2.89-2.96 (m, 4H, Hbenzylic), 7.08 (d, 1H, Harom, 
J=8.3 Hz), 7.24 (d, 1H, Harom, J=8.3 Hz), 7.43-7.61 (m, 4H, Harom), 11.70 (s, 1H, =NOH) ppm; 
13C-NMR (DMSO-d6), δ: 30.56, 32.43, 118.43, 118.69, 130.50, 130.92, 131.02, 131.55, 131.69, 
132.79, 135.87, 136.32, 137.57, 137.67, 152.94 (C=NOH) ppm. 
 
3,7-Dibromo-5-(dimethylaminoethyloxyimino)-10,11-dihydro-5H-dibenzo[a,d]cyclohepta-1,4-diene 
(1). 
 
This compound was prepared by heating the ketoxime 9 (2.1 g, 5.51 mmol), 2-dimethylamino-
ethylchloride hydrochloride (0.95 g, 6.61 mmol) and potassium carbonate (1.68 g, 12 mmol) in acetone 
for 15 hours under an inert atmosphere. After cooling to room temperature, the precipitate was filtered 
off and the solvent was removed from the filtrate under reduced pressure. A brown oil was obtained, 
which crystallized on cooling. The yield was 2.44 g (98%); Rf=0.54 (9:1 dichloromethane-methanol); 
IR (KBr) ν 2920, 2810, 2760, 2040, 1580, 1550 (C=N), 1440, 1380, 1350, 1320, 1290, 1250, 1160, 
1070, 1020 (C-O), 990 (N-O), 910, 880, 810 cm-1; 1H-NMR (CDCl3) δ: 2.32 (s, 6H, N(CH3)2), 2.72 (t, 
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2H, CH2, J=5.8 Hz), 3.02-3.06 (m, 4H, Hbenzylic C-10,11), 4.36 (t, 2H, CH2, J=5.8 Hz), 6.99 (d, 1H, 
Harom C-9,1, J=8.5 Hz), 7.12 (d, 1H, Harom C-9,1, J=8.2 Hz), 7.39 (dd, 2H, Harom C-8,2, J=1.9 Hz), 7.57 
(d, 1H, Harom C-4,6, J=1.9 Hz), 7.72 (d, 1H, Harom C-4,6, J=1.9 Hz) ppm; 13C-NMR (CDCl3) δ: 31.21 
(C-10,11), 32.77 (C-10, 11), 45.70 (N(CH3)2), 57.75 (CH2), 72.91 (CH2), 119.13 (C-3,7), 119.64 (C-
3,7), 129.70 (C-1), 131.33 (C-4,6), 131.96 (C-2,8,9), 154.81 (C=NOR) ppm; Anal. Calcd. 
(C19H20Br2N2O): C 50.46, H 4.46, Br 35.34, N 6.20; Found: C 50.60, H 4.61, Br 35.54 and N 6.04%. 
 
Grignard reaction with 3,7- and 1,7- dibromo derivatives 7 and 8: preparation of dry tetrahydrofuran 
for use in the Grignard reaction: 
 
To Mg-turnings (1.72 g, 70 mmol), a few milliliters of THF (just enough to cover the Mg) and a 
small crystal of iodine were added. A separately prepared solution of ethyl bromide (5.0 mL) in THF 
(20 mL) was added dropwise into the Mg-suspension at such a rate that the reaction mixture kept 
boiling. After the whole solution was added, refluxing of the reaction mixture was continued for 30 
minutes. Additional THF (130 mL) was then added and refluxing was maintained for 2 hours. When 
the Mg-turnings had mostly reacted, the THF was distilled off in a closed system. 
 
Preparation of the free base 
 
Sodium hydroxide and 3-dimethylamino-1-propylchloride hydrochloride were dissolved separately 
in water (10 mL). These two solutions were mixed and the pH was adjusted to ~14. After extraction 
with dichloromethane (3x30 mL), the extracts were dried over anhydrous sodium sulfate and the 
solvent was removed to afford 3.34 g (53%) of the free base. 
 
Grignard reaction 
 
A solution of the free base was prepared by dissolving N,N-dimethylamino-1-propyl-chloride (2.5 
g) in dry THF (20 mL). After that, CaH2 (1.0 g) was added, the suspension was stirred for one hour, 
and filtered. This freshly prepared filtrate was added dropwise over 30 minutes to a small volume of 
dry THF (20 mL), a crystal of iodine and Mg-turnings (0.51 g). The reaction mixture was heated with 
stirring for 2 hours. The solution of the Grignard reagent was cooled to 0 °C and a solution of 3,7-(7) 
or 1,7-dibromodibenzosuberone (8) (3.66 g) in THF (50 mL) was added dropwise. The obtained 
mixture was stirred at room temperature overnight, then poured into a saturated solution of sodium 
chloride and extracted with dichloromethane (3x30 mL). The extract was dried over anhydrous sodium 
sulfate and the solvent was evaporated. The Grignard reaction products 10 and 11 were purified by 
column chromatography on SiO2 with dichloromethane/methanol 9:1 as eluent. 3,7-Dibromo-5-
(hydroxy-5-N,N-dimethylaminopropyl)-10,11-dihydro-5H-dibenzo[a,d]cycloheptane (10): 2.93 g 
(64.7%), mp 145.5-146.5 °C; Rf= 0.47 (9:1 dichloromethane/methanol); IR (KBr) ν 3090 (OH), 2940, 
2920, 2850, 2820, 2780, 2700, 2630, 2330, 1900, 1795, 1580, 1560, 1460, 1420, 1400, 1385, 1350, 
1335, 1290, 1265 (C-N), 1245, 1230, 1205, 1185, 1170, 1150, 1110, 1100, 1065, 1050, 1035, 1005, 
950, 920, 900, 880, 845, 820, 790, 775, 755, 735, 700, 680, 650, 635, 615 cm-1; 1H-NMR (CDCl3) δ: 
1.32 (t, 2H, CH2, J=5.2 Hz), 2.17-2.25 (m, 8H, N(CH3)2+CH2), 2.43-2.47 (m, 2H, CH2), 2.85-2.96 (m, 
Molecules 2005, 10 
 
 
1435
2H, Hbenzylic), 3.32-3.43 (m, 2H, Hbenzylic), 6.93 (d, 2H, Harom, J=8.0 Hz), 7.23-7.27 (m, 2H, Harom), 8.19 
(d, 2H, Harom, J=1.9 Hz) ppm; 13C-NMR (CDCl3) δ: 22.15, 32.68, 44.15, 44.95, 59.50, 75.39 (COH), 
120.13, 129.75, 129.95, 131.89, 135.73, 147.37 ppm; Anal. Calcd. (C20H23Br2NO): C 53.00, H 5.12, 
Br 35.26, N 3.09; Found: C 53.07, H 5.04, Br 35.32 and N 2.97%. 1,7-dibromo-5-(hydroxy-5-N,N-
dimethylaminopropyl)-10,11-dihydro-5H-dibenzo[a,d]cycloheptane (11): 1.50 g (33.1%) of product 11 
was obtained, mp 164.5-167.0 °C; Rf=0.31 (9:1 dichloromethane/methanol); IR (KBr) ν 3030 (OH), 
2970, 2940, 2900, 2840, 2760, 2680, 2640, 2540, 2460, 2320, 1900, 1580, 1500, 1460, 1440, 1400, 
1390, 1380, 1290, 1260 (C-N), 1240, 1200, 1160, 1140, 1100, 1040, 100, 950, 920, 890, 850, 820, 
780, 750, 740, 690, 650 cm-1; 1H-NMR (CDCl3) δ: 1.42 (d, 2H, CH2, C-13), J=4.7 Hz), 2.25 (s, 6H, 
N(CH3)2), 2.37-2.47 (m, 2H, CH2), 2.62-2.69 (m, 1H, CH2), 2.88-2.97 (m, 1H, CH2), 3.20-3.48 (m, 
4H, Hbenzylic C-10,11), 6.98 (d, 1H, Harom, J=8.0 Hz), 7.06 (t, 1H, Harom, J=7.8 Hz), 7.26-7.29 (m, 1H, 
Harom), 7.48 (d, 1H, Harom, J=8.0 Hz), 8.07 (d, 1H, Harom, J=8.0 Hz), 8.17 (d, 1H, Harom, J=1.9 Hz) ppm; 
13C-NMR (CDCl3) δ: 21.93, 31.92, 32.96, 43.61, 44.82 (N(CH3)2), 59.21, 75.80 (COH), 120.20, 
125.98, 126.27, 126.91, 129.82, 129.88, 131.50, 131.87, 135.36, 135.56, 147.35, 147.44 ppm; Anal. 
Calcd. (C20H23Br2NO): C 53.00, H 5.12, Br 35.26, N 3.09; Found: C 53.01, H 4.99, Br 35.23 and N 
2.93%.  
 
Dehydration of products 10 and 11 
 
The hydroxy derivatives 10 or 11 (0.2 g, 0.44 mmol) were dissolved in 85% sulfuric acid (20 mL) 
and stirred for 3 hours at 4 °C. After that, the reaction mixture was slowly diluted with cold water, 
made alkaline with sodium hydroxide and extracted with dichloromethane (3x30 mL). The 
dichloromethane solution obtained was dried over anhydrous sodium sulfate and the solvent was 
removed under reduced pressure to give, in the case of compound 10,  3,7-dibromo-5-(3-N,N-dimethyl-
aminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]cycloheptene (2): 0.18 g (94.0%), mp 98.5-100.5 
°C; Rf=0.34 (9:1 dichloromethane/methanol); IR (KBr) ν 2940, 2850, 2780, 2710, 1880, 1580, 1560, 
1450, 1370, 1260 (C-N), 1220, 1150, 1070, 1050, 1025, 960, 920, 890, 870, 800, 770, 760, 750, 710, 
670 cm-1; 1H-NMR (CDCl3) δ: 2.19 (s, 6H, N(CH3)2), 2.21-2.42 (m, 4H, CH2+CH2 C-13,14), 2.70-
2.95 (m, 2H, Hbenzylic C-10,11), 3.22-3.39 (m, 2H, Hbenzylic C-10,11), 5.90-5.95 (m, 1H, C=CH), 6.90 (d, 
1H, Harom, J=8.2 Hz), 7.09 (d, 1H, Harom, J=8.0 Hz), 7.24-7.35 (m, 3H, Harom), 7.24 (s, 1H, Harom C-4,6, 
J=1.9) ppm; 13C-NMR (CDCl3) δ: 27.76, 31.04, 32.84, 38.73, 45.24 (N(CH3)2), 59.02, 119.25, 119.28, 
129.65, 129.88, 130.38, 130.75, 131.04, 131.18, 131.53, 135.59, 137.94, 140.69, 141.29, 142.22; Anal. 
Calcd. (C20H21Br2N): C 55.19, H 4.86, Br 36.72, N 3.22; Found: C 55.24, H 4.76, Br 36.68 and N 
3.19%. After dehydratation of compound 11 a mixture (0.2 g, 0.44 mmol) of the respective syn- and 
anti-isomers of 1,7-dibromo-5-(3-N,N-dimethylaminopropylidene)-10,11-dihydro-5H-dibenzo[a,d]-
cycloheptene (3) was obtained. The pure anti-isomer was obtained by prolonged stirring in cold 85% 
sulfuric acid at 4 °C for 3 hours and at room temperature for 8 hours. After chromatography 0.14 g 
(73%), Rf=0.39 (dichloromethane/methanol 9:1) of pure 3E were obtained; IR (KBr) ν 2929, 2857, 
2817, 2780, 1673, 1584, 1558, 1477, 1449, 1361, 1264 (C-N), 1231, 1160, 1128, 1041, 969, 897, 817, 
790, 739, 705 cm-1; 1H-NMR (CDCl3) δ: 2.22 (s, 6H, (N(CH3)2)), 2.32-2.34 (m, 2H, CH2), 2.41-2.44 
(m, 2H, CH2), 2.78-2.90 (m, 2H, Hbenzylic), 3.21-3.31 (m, 2H, Hbenzylic), 5.87-5.92 (t, 1H, C=CH, J=7.0 
Hz), 6.91-7.49 (m, 6H, Harom) ppm; 13C-NMR (CDCl3) δ: 27.45, 27.59, 30.80, 31.51, 34.59, 45.04 
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(N(CH3)2), 58.85, 119.26, 127.22, 127.96, 129.73, 131.53, 131.89, 135.49, 135.65, 141.05, 141.25, 
142.09, 142.48 ppm; Anal. Calcd. (C20H21Br2N): C 55.19, H 4.86, Br 36.72, N 3.22; Found C 55.15, H 
5.01, Br 36.94 and N 3.11%.  
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